{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T10:45:10Z","timestamp":1772016310391,"version":"3.50.1"},"reference-count":118,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Oral contraceptives (OCs) are the most widely used form of birth control among women of childbearing potential. Knowledge of potential drug\u2010drug interactions (DDIs) with OCs becomes imperative to provide information on the medication to women of childbearing potential and enable their inclusion in clinical trials, especially if the new molecular entity is a teratogen. Although a number of DDI guidance documents are available, they do not provide recommendations for the design and conduct of OC DDI studies. The evaluation of DDI potential of a new molecular entity and OCs is particularly challenging because of the availability of a wide variety of combinations of hormonal contraceptives, different doses of the ethinyl estradiol, and different metabolic profiles of the progestin component. The aim of this review is to comprehensively discuss factors to be considered such as pharmacokinetics (PK), pharmacodynamics (PD), choice of OC, and study population for the conduct of in vivo OC DDI studies. In this context, metabolic pathways of OCs, the effect of enzyme inhibitors and inducers, the role of sex hormone\u2013binding globulin in the PK of progestins, current evidence on OC DDIs, and the interpretation of PD end points are reviewed. With the emergence of new tools like physiologically based PK modeling, the decision to conduct an in vivo study can be made with much more confidence. This review provides a comprehensive overview of various factors that need to be considered in designing OC DDI studies and recommends PK\u2010based DDI studies with PK end points as adequate measures to establish clinical drug interaction and measurement of PD end points when there is basis for PD interaction.<\/jats:p>","DOI":"10.1002\/jcph.1765","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T04:56:32Z","timestamp":1607057792000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Drug\u2010Drug Interaction Studies With Oral Contraceptives: Pharmacokinetic\/Pharmacodynamic and Study Design Considerations"],"prefix":"10.1002","volume":"60","author":[{"given":"Haiying","family":"Sun","sequence":"first","affiliation":[{"name":"Novartis Institutes for BioMedical Research  East Hanover New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rama","family":"Sivasubramanian","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt. Ltd.  Hyderabad Telangana India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soniya","family":"Vaidya","sequence":"additional","affiliation":[{"name":"Current affiliation: Axcella Health Inc.  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avantika","family":"Barve","sequence":"additional","affiliation":[{"name":"Novartis Pharma  East Hanover New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkateswar","family":"Jarugula","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research  East Hanover New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"National Center for Health Statistics.https:\/\/www.cdc.gov\/nchs\/fastats\/contraceptive.htm. Published2019. Accessed February 17 2020."},{"key":"e_1_2_7_3_1","unstructured":"United Nations Department of Economic and Social Affairs.https:\/\/www.un.org\/development\/desa\/pd\/sites\/www.un.org.development.desa.pd\/files\/files\/documents\/2020\/Jan\/un_2019_contraceptiveusebymethod_databooklet.pdf. Accessed October 16 2020."},{"key":"e_1_2_7_4_1","unstructured":"EMA. ICH guideline M3(R2) on non\u2010clinical safety studies for theconduct of human clinical trials and marketing authorisation for pharmaceuticals.https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m3r2-non-clinical-safety-studies-conduct-human-clinical-trials-marketing-authorisation_en.pdf. Published 2009. Accessed September 15 2020."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1285"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.384"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2006.11.009"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2017.07.003"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.637"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12499"},{"key":"e_1_2_7_11_1","unstructured":"UW Drug Interaction Solutions. University of Washington.https:\/\/www.druginteractionsolutions.org\/. Accessed October 2019."},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003081-198109000-00014"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(99)70120-1"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1974.03240030039023"},{"issue":"1","key":"e_1_2_7_15_1","first-page":"101","article-title":"C. Current Trends in Clinical Combined Oral Contraceptive Drug Interaction Studies in Clinical Pharmacokinetics (ADME)","volume":"8","author":"Choi AY","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"e_1_2_7_16_1","volume-title":"Current Contraceptive Status Among Women Aged 15\u201049 United States, 2015\u20102017","author":"Daniels KAJC","year":"2018"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2004.07.013"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogc.2007.01.001"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2006.07.005"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.81.1.90"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1572546"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098614548857"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.000182"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2010.04.016"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.27.1900"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746020-00003"},{"issue":"3","key":"e_1_2_7_27_1","first-page":"413","article-title":"Sulfation of estrone and 17 beta\u2010estradiol in human liver: catalysis by thermostable phenol sulfotransferase and by dehydroepiandrosterone sulfotransferase","volume":"20","author":"Hernandez JS","year":"1992","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00081.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498258309052280"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(90)90431-P"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198308020-00001"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1987.tb03107.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12745"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(00)00133-5"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(97)00030-9"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(90)90093-B"},{"issue":"3","key":"e_1_2_7_37_1","first-page":"975","article-title":"The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel","volume":"287","author":"Gentile DM","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02382.x"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2007.09.025"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)00893-7"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1998.tb03147.x"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2012.11.004"},{"key":"e_1_2_7_43_1","unstructured":"Allergan. Lo Loestrin Fe prescribing information.https:\/\/media.allergan.com\/actavis\/actavis\/media\/allergan-pdf-documents\/product-prescribing\/NDA-22501-Lo-Loestrin-Fe-PI-CLEAN-08-2017_ver1.pdf. Published2017. Accessed September 16 2020."},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/13625180902968856"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199120010-00002"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(12)90410-X"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(88)90110-2"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199651020-00002"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(93)90332-D"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(90)90553-J"},{"issue":"1","key":"e_1_2_7_51_1","first-page":"5","article-title":"Drug interaction with oral contraceptives","volume":"2","author":"Hillier K.","year":"1978","journal-title":"Fertil Contracept"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00749.x"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01123.x"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.288.6424.1125-a"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1985.218"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1996.03097.x"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1177\/009127009803801109"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70138-4"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2012.01.010"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200204150-00007"},{"issue":"4","key":"e_1_2_7_61_1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/135965350801300415","article-title":"Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low\u2010dose ritonavir in healthy women","volume":"13","author":"Sekar VJ","year":"2008","journal-title":"Antivir Ther"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1725"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1724"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02917.x"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1990.tb05457.x"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1992.tb01773.x"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02539.x"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/0009-9236(95)90172-8"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01665.x"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03519.x"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(08)80010-2"},{"issue":"3","key":"e_1_2_7_72_1","first-page":"4","article-title":"Do antibiotics decrease effectiveness of oral contraceptives?","volume":"61","author":"Cottet C","year":"1996","journal-title":"Oreg Nurse"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(98)80016-1"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006250-200108000-00007"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.285"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199018060-00004"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840030219"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1984.240"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198204013061307"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01381.x"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1984.114"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050543"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00544361"},{"issue":"6","key":"e_1_2_7_84_1","first-page":"821","article-title":"Oral contraceptive steroids impair the elimination of theophylline","volume":"101","author":"Roberts RK","year":"1983","journal-title":"J Lab Clin Med"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1159\/000137961"},{"issue":"3","key":"e_1_2_7_86_1","first-page":"338","article-title":"Increased metabolic clearance of acetaminophen with oral contraceptive use","volume":"60","author":"Abernethy DR","year":"1982","journal-title":"Obstet Gynecol"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.17"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1997.tb04321.x"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.108949"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01868.x"},{"key":"e_1_2_7_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1711-0"},{"key":"e_1_2_7_92_1","unstructured":"Sanofi\u2010Aventis.NDA 21\u2013144\/S\u2010012 KETEK\u00ae (telithromycin) tablets. Published 2007. Accessed May 23 2020."},{"key":"e_1_2_7_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25653"},{"key":"e_1_2_7_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.03084.x"},{"key":"e_1_2_7_95_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182a9b3f1"},{"key":"e_1_2_7_96_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03589-14"},{"key":"e_1_2_7_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1857-9"},{"key":"e_1_2_7_98_1","unstructured":"Gilead.Stribild Clinical Pharmacology and Biopharmaceutics Review(s).https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203100Orig1s000ClinPharmR.pdf:US Food and Drug Administration. Published July 12 2012. Accessed September 16 2020."},{"key":"e_1_2_7_99_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181eb5ff5"},{"key":"e_1_2_7_100_1","unstructured":"Kasserra CHE TreitelM GuptaS O'MaraE.Clinical pharmacology of boceprevir: metabolism excretion and drug\u2010drug interactions [abstract 118]. 18th Conference on Retroviruses and Opportunistic Infections; Boston MA; February 27\u2013March 2 2011."},{"key":"e_1_2_7_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00187-5"},{"key":"e_1_2_7_102_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2003.55602.x"},{"key":"e_1_2_7_103_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/137192"},{"key":"e_1_2_7_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2003.08.009"},{"key":"e_1_2_7_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12085"},{"key":"e_1_2_7_106_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP202142"},{"key":"e_1_2_7_107_1","first-page":"511","volume-title":"Basic and Clinical Endocrinology","author":"Rosen M","year":"2004"},{"key":"e_1_2_7_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(97)00205-9"},{"key":"e_1_2_7_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(96)00183-7"},{"key":"e_1_2_7_110_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.111614"},{"key":"e_1_2_7_111_1","unstructured":"US Food and Drug Administration. Guidance for industry.https:\/\/www.fda.gov\/media\/134582\/download. Published January 2020. Accessed October 16 2020."},{"key":"e_1_2_7_112_1","unstructured":"FDA.Clinical drug interaction studies\u2014study design data analysis and clinical implications. Guidance for Industry.https:\/\/www.fda.gov\/media\/134581\/download. Published 2020. Accessed September 15 2020."},{"key":"e_1_2_7_113_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.121829"},{"key":"e_1_2_7_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(01)00101-8"},{"key":"e_1_2_7_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2004.11.019"},{"key":"e_1_2_7_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2008.00252.x"},{"key":"e_1_2_7_117_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1085"},{"key":"e_1_2_7_118_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx515"},{"key":"e_1_2_7_119_1","doi-asserted-by":"publisher","DOI":"10.1086\/685428"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1765","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.1765","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.1765","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T17:01:42Z","timestamp":1693760502000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.1765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":118,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1002\/jcph.1765"],"URL":"https:\/\/doi.org\/10.1002\/jcph.1765","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"2020-06-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}